The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
AOI is the leading cancer hospital chain of South Asia operating 16 cancer hospitals in the region
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Highlighting KEYTRUDA & expanding cancer pipeline
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
NEJM study shows strong protection across strains
Approval strengthens the company’s growing international anti-infective portfolio
Subscribe To Our Newsletter & Stay Updated
